Shaping the Future of Bioorganic and Medicinal Chemistry

ME Conferences takes a lot of privilege to welcome all the scholars and researchers from all around the world to expatiate about their respective scientific research at 2nd World Congress on Bioorganic and Medicinal Chemistry which is CPD accredited.

2^nd World Congress on Bioorganic and Medicinal Chemistry scheduled on November 22-23, 2019 Dubai, UAE goes with the theme Shaping the Future of Bioorganic and Medicinal Chemistry. Bioorganic Medicinal 2019 is an international event focusing on the core knowledge and major advances in the ever-expanding field of Bioorganic and Medicinal Chemistry by attracting experts on a global scale. It is a global platform to discuss the innovative researches and developments in the Bioorganic and Medicinal Chemistry. It is a golden opportunity to meet eminent personalities and to learn the latest technological advancements.

The distinctive features of the conference includes

·         Agro Chemistry

·         Analytical Chemistry

·         Biochemistry

·         Biological Drug Targets

·         Bioorganic Chemistry

·         Chemical Biology

·         Combinatorial Chemistry

·         Computational Chemistry

·         Drug Discovery, Design and Development

·         Environmental Chemistry

·         Food Chemistry

·         Green Chemistry

·         Medicinal Chemistry

·         Molecular Biology

·         Nanochemistry

·         Organic Chemistry

·         Pharmaceutical Chemistry

·         Pharmacokinetics & Pharmacodynamics

For more details visit our website

If you want to be a part of this esteemed event drop a mail at bioorganicmedicinalchemistry@gmail.com

What will be the Future of Antimicrobials?

Bacterial resistant- This study may aid in preventing antibacterial resistance!!

Bacteria are microscopic single-celled organisms. It consists of a single cell with a simple internal structure. Most of the bacteria are harmless and beneficial. Only a few species are harmful and cause diseases. Antimicrobials are the agent that kills or prevent the growth of microorganisms such as bacteria, viruses or fungi. Nowadays bacteria are rapidly evolving and becoming resistant to these antimicrobials.

The new materials researchers have designed and built allow antibacterial to be more potent and have the ability to wipe out bacteria at smaller concentrations than the antibacterial can do on their own. Scientists have discovered a new drug delivery system that may help prevent bacterial infections.

The researchers synthesised nanostructured silica particles, considered to be promising drug carriers, that contained payloads of an antimicrobial agent.

According to the previous study, they found that the particles were effective at killing two human bacterial pathogens.

While antibiotics are taken orally and that they become extensively distributed throughout the body. But the new mechanism allows compounds to slowly release antimicrobials into local environments, resulting in high amounts of the molecule in a specific location.

Interestingly, the particles were more effective at killing the bacteria which may highlight a more efficient mechanism for drug delivery.

This is because the newly designed nanomaterials allow the antibacterial to be localised, released slowly and attack the microorganism more effectively

Researchers said the study could lead to the development of new microscopic particles containing drugs, antiseptics or pesticides that may increase the effectiveness of the therapy and aid in preventing antibacterial resistance. 

Is Turmeric GOOD or BAD?

This new research about turmeric will Surprise you!!

Turmeric is a flowering plant of the ginger family, Zingiberaceae. Curcumin is the active compound that found in turmeric which has effective biological properties. Turmeric has been used in Asia for thousands of years and is a major part of medicine.

Turmeric might be the foremost effective dietary supplement in presence. Turmeric milk that we were consuming for years have become a new discovery in the West as a. “superfood”

Medically speaking, turmeric has traditionally been used to enhance immunity, heal wounds and improve anti-oxidants in the body. Researches have proven that the right dosage of turmeric, consumed in any form can assist Alzheimer's disease, reduce coronary heart attacks and additionally enhance overall brain function.

For a healthy body, specialists and researchers recommend ingesting up to 500 mg of turmeric each day to hold better health. The dosage also can increase in case of serious illnesses.

A research proves that turmeric has healing properties when used both as a spice as well as medicine, it may not be really powerful because the body faces a difficult time ingesting it. If curcumin would not certainly make its way to the intestine and digestive system, it might as well be good for nothing.

Curcumin is the active compound found in turmeric when it enters into the bloodstream will not be absorbed easily that makes no benefit. Researchers conducted a study by observing a trail with a group of patients who utilized turmeric to treat their illness but found zero improvements.

By combining turmeric's anti-inflammatory properties with sugary drinks and may be quite toxic and fatal.

At the same time, researchers warned against eliminating turmeric from the diet. Curcumin may not get absorbed easily however it is an effective component with many uses. Specialists suggest the use of turmeric with black pepper because Black pepper contains a herbal compound which helps in its absorption. If no longer medicinal, specialist’s support that turmeric with all its holistic healing benefits would not do the body any kind of bad.

Toxic Blooms

Researchers Reveal Genetic Basis for Toxic Algal Blooms

The algal bloom is a rapid increase or accumulation in the population of algae in freshwater or marine water systems and is recognized by the discolouration in the water from their pigments.

A Harmful Algal Bloom (HAB) is an algal bloom that reasons terrible effects to other organisms through the production of natural toxins, mechanical damage to different organisms, or by means of another manner.

In humans, the toxin can cause rashes, skin lesions, headaches and stomach pain.

Despite decades of research, the trigger that causes algal blooms to begin poisoning their environment has long confounded scientists.

Now, researchers have found the genetic underpinning of domoic acid, a harmful neurotoxin. In a new, researchers describe three genes responsible for producing domoic acid in the phytoplankton Pseudo-nitzschia.

Monitoring how the clusters of genes behave could one-day yield information on which environmental or biological triggers are responsible for activating them. That information could help fisheries and public health officials predict when harmful algal blooms will occur, allowing them to effectively prepare.

The "very small" cluster of genes responsible for the production of the toxin is a relatively rare phenomena compared to other similar organisms, indicating that they may serve some important biological function.

Researchers say "It's not there to make us sick. There are different theories for why it's there, including serving as a feeding deterrent,"

They speculate the toxin may deter organisms that would feed upon the algae.  Or it may be that the toxin allows algae to chemically bond to nutrients, such as iron, present in the water.

The discovery of these genes will allow us to explore many theories

Join Your Hands for a Good Cause

World Congress on Bioorganic and Medicinal Chemistry scheduled on November 12-13, 2018 Dubai, UAE goes with the theme Explore the latest trends in Bioorganic and Medicinal Chemistry.

Why Attend?

Bioorganic Medicinal 2018  is an international event focusing on the core knowledge and major advances in the ever-expanding field of Bioorganic and Medicinal Chemistry by attracting experts on a global scale. It is a global platform to discuss the innovative researches and developments in the Bioorganic and Medicinal Chemistry. It will be a golden opportunity to meet eminent personalities and to learn the latest technological advancements.

The distinctive features of the conference includes

·         Pharmaceutical Chemistry

·         Structural & Medicinal Biochemistry

·         Biological Drug Targets

·         Drug Design, Discovery and Development

·         Drug delivery Techniques

·         New Trends in Medicinal pharmacy

·         Global Chemical Analysis

·         Organic Chemistry in Today’s Life

·         Bioorganic and Medicinal Chemistry

·         Medicinal Chemistry

·         Pharmacokinetics & Pharmacodynamics

·         Organic Chemical Engineering

·         Medicinal Biochemistry

·         Computational Chemistry

·         Chemical Biology

Our Honourable Organizing Committee:

 Our Guest of Honor:

We are privileged to have Dr.Anthony Melvin Crasto as our honourable guest.

Our Renowned Speakers

Poster Presentations:

For all the speaker’s details visit our Scientific Program

If you want to be a part of our international summit contact

Claira Williams @ medicinalchemistry@memeetings.net

A Historic FLUORINE Discovery

Fluorine is one of the foremost crucial components of life. In its fluoride form, it is a mineral with anti-acid properties utilized in toothpaste and drinking water to prevent dental cavities. This small, non-toxic element is also broadly utilized by medicinal chemists in cancer treatment, antibiotics, anti-depressants, steroids and different drugs. Fluorine is regular in modern drugs as it stabilizes drugs and improves their biological activity.
For many years, researchers have been studying the regulation of thiols, compounds that affect a variety of biological functions in mammals including redox stress levels, energy balance, cellular signalling, coronary heart health, and autoimmune and neurological conditions. While thiol levels are stable, people are normally healthy. Once they increase too much and for too lengthy, situations including rheumatoid arthritis, breast cancer, Alzheimer's and Parkinson's diseases can develop.
Cysteine dioxygenase (CDO) and cysteamine dioxygenase (ADO) regulates the thiol levels in our body. While the thiol levels are increased, CDO and ADO develop catalytic amplifiers to quickly eliminate thiol from the body. Scientists don't yet understand exactly how the enzymes make the amplifiers.

The scientists carried out a method on CDO known as genetic code expansion.
The researchers made a new form of CDO with two exceptionally strong carbon-fluorine bonds. This need to have made it tougher for the enzyme to break those carbon-fluorine bonds and bring its catalytic amplifier. What they found, however, surprised them. They observed that the modified CDO was still capable to break its carbon-fluorine bonds to generate its full catalytic assembly.
This is the first time that scientists have confirmed the cleavage (breakage) of a carbon-fluorine bond thru oxidation in proteins. Because of this, it may be possible that human bodies are able to break these bonds in the drugs that are consumed.
Researcher’s additionally uncovered clues as to how thiols generate their catalytic amplifiers after the proteins are built.
More than 20% of pharmaceutical drugs contain fluorine. Due to their energy, fluorine-carbon bonds resist normal drug metabolism and may extend the useful lifetime of the drug in the body. Fluorine in drug molecules can also increase their capability to cross membrane barriers and enter cells. That the carbon-fluorine is strongly safe to cleavage could be a long-held conviction in medicinal chemistry.
Pharmaceutical companies have to remind that fluorine chemistry is very complex. Even though valuable, it is highly recommended to proceed with caution, because there's still a lot to learn.
Understanding the C-F bond is important to our understanding of drug design and enhancing the lives of patients.

ENZYMES: Key for Drug Development

Researchers are mapping the characteristic of particular enzymes which may also facilitate the development of new drugs to combat bacterial contamination, cancer and probably neurodegenerative diseases like autism, Down syndrome, Parkinson's disease and Alzheimer's.

Sulfur is one of most abundant elements in the body however little is thought approximately the enzymes concerned in its metabolism

Autistic, Alzheimer and Down syndrome patients all reveal abnormal sulfur metabolism. If we will work out how human sulfur-oxidizing enzymes function, or more crucially, how their behaviour changes in bacteria or in specific diseases, this information may be used for the rational design of drugs targeted for those diseases. Presently, no such technology exists.

Retro-engineering the sulfur oxidation method and mapping out of the chemical mechanism of 3 key enzymes—cysteine dioxygenase, cysteamine dioxygenase, and three-mercaptopropionic acid dioxygenase—to provide the necessary framework to increase effective treatments and drugs for different disease states.

By means of comparing the behaviour of these enzymes in human beings to bacteria, we also can open up possibilities to stamp out "superbugs" via offering an alternate method to disrupt bacterial metabolism without adversely affecting the patient, That is specifically important as we are now seeing widespread drug-resistant bacterial strains

Researchers use rapid-mix, freeze-quench techniques to 'trap' and monitor the progress of chemical reactions at millisecond intervals. Analysis of those consequences offers a step-by-step picture of how these enzymes function in both mammals and bacteria.

They look at fundamental life processes outside the traditional sphere of biochemistry and employs very current strategies to analyze enzyme function and regulation

By providing the fundamental scientific background had to develop treatments for important conditions and they want to make a real impact on the development of new scientific solutions

A Novel Drug for Liver Cancer

Hepatocellular carcinoma (HCC) accounts for more than 90% of all liver cancers. Due to its restricted treatment options and poor diagnosis, there may be presently an unmet need for alternative, greater effective treatments. In a new study, researchers have developed a unique peptide drug known as FFW that might probably reduce tumor growth and gradual development of cancer.

Previous research has examined SALL4, a protein related to tumor growth, as a prognosis marker and drug target for HCC, in addition to other cancers. However, it's been previously categorized as an “undruggable target,” according to the researchers.

In prior studies, they observed that the SALL4 protein works with another protein, NuRD, to make an association typically imperative for the enhancement of cancers counting HCC. Drug molecules that act on protein interactions which incorporate SALL4-NuRD frequently require the target proteins to have a small “pocket” in their 3-d structure in which the drug molecule can reside and take effect.

Rather than trying to find ‘pockets’ on SALL4, the research group designed a bio-molecule to block the interaction between SALL4 and NuRD. In lab experiments, blocking the interaction has brought about tumor cell death and decreased movement of tumor cells.

This bio-molecule, peptide FWW, is a small chain of amino acids which can interfere with these interactions and efficiently block the large protein-protein interaction surface, without needing a “pocket” to take effect. Moreover, the researchers observed that FWW should reduce the growth of Sorafenib-resistant HCC, while utilized in combination with Sorafenib. 

Focusing on the SALL4-NuRD interaction need to have vital implications for the treatment of HCC, this can translate to a broader range of cancers with accelerated SALL4. In the latest work, the research team has additionally demonstrated a powerful approach to appropriately target oncogenes formerly considered undruggable.

“Moving forward, researchers hope to analyze how the targeting of these protein interactions may pan out in different cancer types.”

Alcoholism and Addiction

A drug that decreases alcohol's effects on the brain

Alcohol use disorders may have devastating effects on a person's health, relationships, and finances. But for some, the feeling they get when taking a drink temporarily outweighs those other issues. Researchers have built up a novel medication that declines alcohol's effects on "reward system," causing rats to self-administer the beverage less frequently.

the brain’s "

 Once devoured, the liquor goes into the brain and associated with the neurotransmitters and their receptors incorporating some worried in reward-system pathways. When activated, these pathways can cause emotions of pleasure, relaxation, and craving. Even though alcohol-treatment pills that interfere with the reward system exist, these pills aren't very powerful and may have extreme aspect results. For effective treatment, researchers concentrated their efforts on a protein receptor known as GPR88 which is found dominatingly in reward-associated regions of the brain. Previous studies on genetically modified mice which lack GPR88 protein showed that these animals seek and consume alcohol more than normal mice. This led the researchers to surprise if a drug that stimulates GPR88 ought to reduce alcohol cravings. They had formerly developed a synthetic small molecule that activates GPR88 in vitro; however, this molecule couldn't effectively pass the blood-brain barrier.

The researchers tweaked the structure of the compound to make it more likely to go into the brain. They arrived at a molecule called RTI-13951-33 that become effective, selective for GPR88 and will pass the blood-brain barrier. Whilst given RTI-13951-33, non-engineered rats drank less alcohol than earlier than they received the drug. In comparison, the rats gave themselves sugar water on the equal frequency with or without the drug. The researchers are now analyzing the molecule in both wild-type mice and those that lack the GPR88 receptor to show that the drug is specific for that receptor.

A New Drug Puts Cancer Cells Permanently to 'SLEEP'

Scientist discovered anti-cancer drug without the usual side effects of conventional cancer treatments.

Research up to now has proven progress in delaying cancer relapse in addition to treating some forms of cancer.

The technique of preventing the growth of tumors occurs without damaging any cell's DNA, which takes place in traditional treatments including chemotherapy and radiotherapy.

The future of cancer therapy might be is to have directed and focused treatments so as to work on specific patient groups. A new kind of approach to cancer therapy that is preventing cancer cells from growing, however, leaving the normal cells especially unaffected and that's by harnessing the body's normal defenses against unrestricted growth.

The development of the drug is at a pre-clinical stage. The research indicates that by targeting certain proteins recognized to play the primary function in the development of cancer, doctors can essentially prevent the disease.

These proteins are known as KAT6A and KAT6B and they're proteins that affect certain genes most commonly observed in cancers. The disease-causing protein that has been targeted has actually not been able to be targeted before with a small-molecule potential drug. Researchers developed a small molecule that inhibits these proteins.

The way that those epigenetic drugs work especially this drug is that it freezes the cell, however, does not kill it off. In case you are at a late stage disease and have lots of tumors in your body, we obviously need to get rid of that first before seeking to prevent the cells from growing. This drug could be definitely beneficial after the usage of initial therapy that gets rid of the original tumor mass and we might use that new type of epigenetic drug to prevent any tumors from developing back, that's a truly beneficial concept and idea.

Artificial Intelligence Seeks Out New Drugs

How drug candidates interact with their target to treat disease is the key to drug development?

Computers and chemists have been friends for a long time. But when it comes to drug discovery, current computational methods are often too drawn out and inefficient to identify the mechanism of action of drugs. Now, a multidisciplinary team of researchers believes artificial intelligence could help out in pharmacology studies. The team’s new approach successfully identified a potent inhibitor for 5-lipoxygenase, an enzyme that is over-expressed in a range of human tumors.

Identifying how drug candidates interact with their target to treat disease is key to drug development. Artificial intelligence provides research hypotheses that need to be experimentally confirmed but in a much faster and economical way.

Machine learning can go way beyond more classical molecular docking. The new artificial intelligence tool does not depend on the structure of proteins so it can be applied in cases where molecular docking might not. This tool is also quicker, hence cheaper. ‘Docking tends to be computationally expensive, whereas we can profile one molecule against thousands of drug targets in less than 10 minutes.

Researchers relied on a huge database of compounds and drug targets they used to ‘teach’ a single desktop computer. They used two different machine learning methods: ‘One gives a bind/don’t bind answer … and the other use several decision trees to predict an affinity value. Then, the algorithm gives a prediction. In this case, it suggested likely targets for the natural product β-lapachone – among them enzyme 5-lipoxygenase. Machine learning allows us to leverage statistical patterns found in data. When high-quality datasets exist, machine learning can model these phenomena much faster and cheaper … accelerating efforts for the discovery of novel drugs.

The team’s chemists also synthesized a set of eight β-lapachone analogues, and tested their binding affinity to 5-lipoxygenase. None of them outperformed β-lapachone anticancer activity, however. The algorithm had found a perfect match. This highlights the importance of the structure and substitution pattern for bioactivity. To further analyze how β-lapachone binds to its target enzyme, they created enzyme models and carried out computational studies that confirmed what they had found in the lab – β-lapachone binds strongly to the enzyme’s active site.

In future artificial intelligence will become essential in the search for, and development of, new ligands and drug candidates. Chemistry labs will almost certainly change thanks to these new techniques. Artificial intelligence will be integrated into all aspects: simulation, experimental planning, and characterization. 

For more details visit: https://bioorganic-medicinal.chemistryconferences.org

A New Way For Producing Medical Therapeutic Proteins

Bacterial systems are some of the simplest and most effective platforms for the expression of recombinant proteins. They are more cost-effective compared to other methods. However, in addition to the target recombinant proteins, cells also produce a large number of endogenous proteins, including SlyD. It is a small protein consisting of 3 domains. Its C-terminal region is rich in histidine residues, therefore SlyD exhibits a high affinity for the 2-valent ions and is purified together with the target proteins in the course of metal-affinity chromatography. This results in the need for additional purification steps and, as a consequence, increases the cost of the technological process for obtaining therapeutic recombinant proteins.

Researchers have obtained a series of E. colistrains deficient in the SlyD/SlyX genes. The strains were engineered using λ-red mediated chromosomal deletion.

The sequence of SlyD/SlyX in the E. coli genome was replaced by a gene responsible for resistance to the antibiotic kanamycin that was flanked on both sides by FRT sites, from where it was later removed by FLP recombinase.

Using the example of recombinant bispecific protein MYSTI-2 consisting of two different modules, which are active centers of antibodies against mouse proteins F4/80 and TNF, the scientists compared the activity of proteins isolated from the original and mutant strains. As a result of the study, it was determined that the removal from the E. coligenome of the SlyD and SlyX genes, which presumably encode chaperones that support the spatial structure of Escherichia coli proteins, does not result in a disruption of recombinant proteins' functional activity.

By obtaining original E. coli strains, the researchers were able to solve the problem of contamination of recombinant proteins and to ensure their successful single-stage purification by metal-affinity chromatography.

The obtained set of slyD/slyX-deficient strains of E. coli can be used to produce in a pure form a wide range of prokaryotic and eukaryotic proteins, including medical therapeutic proteins. This makes the development and production of new medicinal and preventive biological preparations easier, simpler and cheaper.

What will be the Future of Existing Drugs..??

Combining drugs and the future

Drug combinations alter the effectiveness of antibiotics

The efficiency of antibiotics might be altered by combining them with each other, non-antibiotic drugs or else even with food additives. Depending on the bacterial species, a few combinations stop antibiotics from functioning to their complete capacity as others begin to overcome antibiotic resistance.

Succeeding antibiotic resistance

Overuse and misuse of antibiotics have led to significant antibiotic resistance. Particular combinations of drugs can assist in preventing multi-drug resistant bacterial infections; however, they may be largely unexplored and infrequently utilized in clinics

Though most of the examined drug combinations reduced the antibiotics’ effect, there were over 500 drug combinations which improved the antibiotic effect. These positive pairings also examined in multi-drug resistant bacteria, they have been found to improve antibiotic effects.

When vanillin - the compound that gives vanilla its exclusive taste - became paired with one specific antibiotic called spectinomycin, it helped the antibiotic to enter bacterial cells and inhibit their growth. Spectinomycin is rarely used these days because of the bacterial resistance that was developed against it.

Pairings this may increase the arsenal of weapons in the war against antibiotic resistance.

However, vanillin lessened the effect of many different kinds of antibiotics. Vanillin works in a similar manner to aspirin to reduce many antibiotic actions - even though its results in human cells have not been examined, they’re most likely different.

According to researchers, combinations of drugs that lower the effect of antibiotics may also be beneficial to human health. Antibiotics can cause collateral damage and side effects because they target healthy bacteria as well. However, the effects of these drug combinations are particularly selective, and often only affect some bacterial species. In the future, we might utilize drug combinations to specifically stop the harmful impacts of antibiotics on healthy bacteria. This will also decrease antibiotic resistance development, as healthy bacteria might not be sited under pressure to develop antibiotic resistance that might afterward be transferred to harmful bacteria.

For more details visit: https://bioorganic-medicinal.chemistryconferences.org